Tamoxifeno y antidepresivos: ¿Antagonistas en la prevención del cáncer de mama? / Antagonism of tamoxifen and antidepressants among women with breast cancer
Rev. méd. Chile
;
139(1): 89-99, ene. 2011. ilus
Article
in Spanish
| LILACS
| ID: lil-595271
ABSTRACT
Tamoxifen is used as an adjuvant therapy to reduce breast cáncer recurrence among women with estrogenreceptor positive tumors. Antidepressants are also com-monly used in such women, to treat depression or to manage hotflush.es, afrequent tamoxifen secondary effect. Some antidepressants couldpotentially inhibit cytochrome P450 2D6, required to actívate tamoxifen, interfering with its action. Although there is not a clear cut directive on the subject, it is nowadays recommended to treat women with antidepressants with the lower cytochrome P450 2D6 inhibition potential to avoid apossible antagonism that may reduce tamoxifen s prevention of breast cáncer recurrence at least in some patients with CYP2D6 genetic variation. The recommended antidepressants are desvenlafaxine, milnacipran, venlafaxin, escitalopram and citalopram.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Tamoxifen
/
Breast Neoplasms
/
Estrogen Antagonists
/
Antidepressive Agents
Type of study:
Practice guideline
Limits:
Female
/
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2011
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Clínica Oncológica Fundación Arturo López Pérez/CL
Similar
MEDLINE
...
LILACS
LIS